Associations Between Adding a Radial Artery Graft to Single and Bilateral Internal Thoracic Artery Grafts and Outcomes:Insights From the Arterial Revascularization Trial. by Taggart, David et al.
                          Taggart, D., Altman, D., Flather, M., Gerry, S., Gray, A., Lees, B., ... the
ART (Arterial Revascularization Trial) Investigators (2017). Associations
Between Adding a Radial Artery Graft to Single and Bilateral Internal
Thoracic Artery Grafts and Outcomes: Insights From the Arterial
Revascularization Trial. Circulation, 136(5), 454-463.
https://doi.org/10.1161/CIRCULATIONAHA.117.027659
Peer reviewed version
License (if available):
Unspecified
Link to published version (if available):
10.1161/CIRCULATIONAHA.117.027659
Link to publication record in Explore Bristol Research
PDF-document
This is the accepted author manuscript (AAM). The final published version (version of record) is available online
via AHA Journals at https://doi.org/10.1161/CIRCULATIONAHA.117.027659 . Please refer to any applicable
terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
  
The Effect of an Additional Radial Artery on Single and Bilateral Internal Thoracic 
Artery Grafts. Insights from the Arterial Revascularization Trial. 
David P Taggart1 MD PhD, Douglas G Altman2 DSc, Marcus Flather3 MD, Stephen Gerry2 
MSc, Alastair Gray4 PhD, Belinda Lees1 BSc PhD, Umberto Benedetto5 MD PhD; on behalf 
of the ART investigators  
1Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Oxford, 
UK;  
2Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology & 
Musculoskeletal Sciences, University of Oxford, Oxford, UK;  
3Norwich Medical School, University of East Anglia and Norfolk and Norwich University 
Hospitals NHS Foundation Trust, Norwich, UK 4Department of Public Health, Health 
Economics Research Centre, University of Oxford, Oxford, UK;  
5Bristol Heart Institute, University of Bristol, School of Clinical Sciences, United Kingdom;  
 
Taggart David David.Taggart@ouh.nhs.uk 
Doug Altman doug.altman@csm.ox.ac.uk 
Marcus Flather m.flather@uea.ac.uk 
Stephen Gerry stephen.gerry@csm.ox.ac.uk  
Alastair Gray alastair.gray@dph.ox.ac.uk 
Belinda Lees belinda.lees@nds.ox.ac.uk  
Umberto Benedetto umberto.benedetto@hotmail.com 
 
 
Corresponding Author 
Umberto Benedetto MD PhD 
Bristol Heart Institute, University of Bristol 
Senate House, 
Tyndall Avenue, 
Bristol, BS8 1TH, UK 
Tel: +44 (0)117 928 9000 
Email: Umberto.benedetto@hotmail.com 
 
total word count: 2930 
  
  
Abstract 
Background: Whether the use of the radial artery (RA) can improve clinical outcomes in 
coronary artery bypass graft (CABG) surgery remains unclear. The Arterial Revascularization 
Trial (ART) was designed to compare survival after bilateral internal thoracic artery (BITA) 
over single left internal thoracic artery (SITA). In the ART, a large proportion of patients 
(~20%) also received a RA instead of a saphenous vein graft (SVG). We aimed to investigate 
the impact of using the RA instead of SVG to supplement SITA or BITA grafts by performing 
a post-hoc analysis of the ART. 
Methods: Patients enrolled in the ART (n=3102) were classified based on conduits actually 
received (as treated). The analysis included 2737 patients who received the RA (RA group, 
n=632) or SVG only (SVG group, n=2105) in addition to SITA or BITA grafts. The primary 
endpoint was the composite of myocardial infarction, cardiovascular death and repeat 
revascularization at 5 years. Propensity score matching and stratified Cox regression were used 
to compare the two strategies.  
Results: MI, cardiovascular death and repeat revascularization cumulative incidence was 
2.3%(95%CI 1.1-3.4), 3.5%(95%CI 2.1-5.0) and 4.4%(95%CI 2.8-6.0) in the RA group and 
3.4%(95%CI 2.0-4.8), 4.0%(95%CI 2.5-5.6) and 7.6%(95%CI 5.5- 9.7) in the SVG group 
respectively. The composite endpoint was significantly lower in the RA group (8.8%;95%CI 
6.5-11.0) when compared to SVG group (13.6%;95%CI 10.8-16.3) (P=0.005). This effect was 
present when the RA was used to supplement both SITA and BITA grafts (interaction P=0.62) 
Conclusions: This post-hoc ART analysis showed that an additional RA was associated with 
reduced mid-term major adverse cardiac events when used to supplement SITA or BITA grafts.  
 
  
  
Clinical Perspective  
• What is new? The Radial Artery (RA) has been associated with superior angiographic 
patency rates when compared to saphenous vein graft (SVG) but the clinical impact of 
using the RA remains unclear. We found that the RA  used to supplement either single 
or bilateral internal thoracic artery grafts instead of SVG only, was associated with a 
significant reduction of major adverse cardiac events with a significantly lower rate of 
reintervention and marginal reduction in cardiovascular death and subsequent 
myocardial infarction.  
• What are the clinical implications? The RA graft is simple to perform as its calibre and 
handling properties are similar to vein grafts and in view of its clinical benefit it is an 
ideal conduit to achieve multiple arterial grafting and improve patients’ outcomes.  
 
  
  
Introduction 
Despite increasing interest in additional arterial conduits during coronary artery bypass graft 
(CABG) surgery [1], the search for the optimum additional arterial conduit to supplement the 
left internal thoracic artery continues. The radial artery (RA) has been shown to provide better 
patency rate than saphenous vein grafts (SVG) [2,3] but whether this translates into superior 
clinical outcomes remains unclear. A few randomized controlled trials investigating the effect 
of the RA on clinical outcomes were underpowered to detect difference in clinical outcomes 
[4-6]. On the other hand, observational studies that have focused only on survival have reported 
discordant results [7-16].   
The Arterial Revascularization Trial (ART) was designed to compare survival after bilateral 
internal thoracic artery (BITA) over single left internal thoracic artery (SITA). The interim 
mid-term results (5 years) recently reported no difference between the groups [1]. A large 
proportion of the ART patients (~20%) received the RA as second conduit to supplement SITA 
graft or as third conduit to supplement BITA grafts, making the ART the largest series of RA 
grafting in the context of a randomized trial involving SITA or BITA.  
We aimed to investigate the impact of the effect when the RA when used to supplement either 
SITA or BITA grafts by performing a post-hoc analysis of the ART.  
Methods 
The present study is a post-hoc analysis of 5 year outcomes of the ART trial. This research 
adheres to the principles set forth in the Declaration of Helsinki 
(http://www.wma.net/en/30publications/10policies/b3/index.html). In the ART, the use of the 
RA was based on surgeon’s discretion. For the purpose of the present analysis, patients enrolled 
in the ART (n=3102) were classified based on conduits actually received according (as treated 
principle). The present analysis compared the strategy using the RA with or without additional 
  
SVG (RA group) versus SVG only (SVG group) to supplement single or bilateral internal 
thoracic artery grafts (SITA and BITA).  
The following patients were excluded from the present analysis: neither SVG nor RA used 
(n=328); patients receiving SVG but neither SITA nor BITA graft (n=30); patient receiving the 
RA but neither SITA nor BITA used (n=7).  
Trial design 
The ART was approved by the institutional review board of all participating centers, and 
informed consent was obtained from each participant. The protocol for the ART has been 
published [17]. Briefly, the ART is a 2-arm, randomized multicenter trial conducted in 28 
hospitals in 7 countries, with patients being randomized equally to SITA or BITA grafts. 
Eligible patients were those with multivessel coronary artery disease undergoing CABG 
including urgent patients (grafting recommended in case of target stenosis ≥75%). Only 
emergency patients (refractory myocardial ischemia/cardiogenic shock) and those requiring 
single grafts or redo CABG were excluded.  
Follow-up  
Questionnaires were sent to study participants by post at 6 months and every year after surgery. 
No clinic visits were planned apart from the routine clinical 6-week post-operative visit. 
Participants were sent stamped addressed envelopes to improve the return rates of postal 
questionnaires. Study co-ordinators contacted participants by telephone to alert them to the 
questionnaire’s arrival and to ask them about medications, adverse events and health services 
resource use. 
Study outcomes  
The primary outcome for this analysis was the composite of major adverse cardiac events 
(MACE) at 5 years including cardiovascular (CV) death, myocardial infarction (MI) and repeat 
  
revascularization.  The effect of the RA on MACE individual components and overall mortality 
was also investigated.  
Hospital outcomes analysed were: hospital mortality, return to theatre, postoperative intra-
aortic balloon pump (IABP), renal replacement therapy, Sternal wound infection, MI, 
cerebrovascular accident (CVA), repeat revascularization and postoperative atrial fibrillation 
(POAF).  Adverse events were adjudicated by a member(s) of the Clinical Event Review 
Committee blind to the surgical procedure.  
Statistical Analysis 
For baseline characteristics, variables are summarised as mean and SD for continuous variables 
and percentage for categorical variables. Multiple imputation (m=3) was used to address 
missing data. Rubin’s method [18] was used to combine results from each of m imputed data 
sets (Amelia R package).  Due to lack of randomization with regards to receiving RA, a 
propensity score (PS) was generated for each patient from a multivariable logistic regression 
model based on pre-treatment covariates as independent variables with RA versus SVG as a 
binary dependent variable [19]. Covariates included in the PS model were: age, female gender, 
body mass index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP) at 
admission, creatinine, New York American Heart functional class (NYHA), unstable angina 
(UA), treated hypertension, treated hyperlipaemia, diabetes mellitus (DM), smoking, chronic 
obstructive pulmonary disease (COPD), peripheral vascular disease (PVD), transient ischemic 
attack (TIA), cerebrovascular accident (CVA), myocardial infarction (MI), percutaneous 
coronary intervention (PCI), atrial fibrillation (AF), left ventricular ejection fraction (LVEF), 
dual antiplatelet therapy (DAPT), off-pump surgery; bilateral internal thoracic artery (BITA); 
left main stem disease (LMDS), left anterior descending artery (LAD) disease; circumflex 
artery (CX) disease; diagonal branch (DIA) disease; right coronary artery (RCA) disease. Pairs 
of patients were derived using greedy 1:1 matching with a calliper of width of 0.2 standard 
  
deviation of the logit of the PS (nonrandom R package). The quality of the match was assessed 
by comparing selected pre-treatment variables in propensity score–matched patients using the 
standardized mean difference (SMD), for which an absolute standardized difference of greater 
than 10% is suggested to represent meaningful covariate imbalance. McNemar's test and paired 
t test were used to assess the statistical significance of the risk difference in short term outcomes 
in the matched sample [19]. A Cox regression model, stratified on the matched pairs [19] was 
used to estimate the treatment effect on the primary outcome and overall mortality. This 
approach accounts for the within-pair homogeneity by allowing the baseline hazard function 
to vary across matched sets (survival R package). Competing risk analysis (prodlim and 
riskRegression R packages) was used to estimate the treatment effect on the primary endpoint 
individual components.  As sensitivity analysis the effect of RA was tested in a mixed effect 
Cox model to account for clustering effect due to individual surgeons and centres [20] 
(http://CRAN.R-project.org/package=coxme). The effect of RA was also adjusted for 
medication at discharge including aspirin, clopidogrel, beta-blockers; calcium channel 
antagonists (CCA); statins; angiotensin converting enzyme inhibitors (ACEI) and angiotensin 
receptors blockers (ARB). Finally possible effect modifiers tested using interaction analysis 
were: Age < and ≥ 70 years; female vs male gender; diabetes vs non diabetes; reduced vs 
preserved LVEF; SITA vs BITA graft; off- vs on-pump surgery.  
All p-values <0.05 were considered to indicate statistical significance. All statistical analysis 
was performed using R Statistical Software (version 3.2.3; R Foundation for Statistical 
Computing, Vienna, Austria). 
Results 
Study sample 
The final population included 2737 patients who received the RA (RA group, n=632) or SVG 
only (SVG group, n=2105). Among those who received the RA, SITA graft was used in 359 
  
patients (57%) and BITA grafts was used in 273 patients (43%). In the RA group, 397 (63%) 
patients underwent total arterial revascularization while the remaining 235 (37%) received 
additional SVG. In the SVG group, 1330 patients had SITA graft (63%) and the remaining 775 
(37%) had BITA grafts.  
Grafts configuration and targets details 
Graft configurations and targets characteristics in the RA and SVG groups are summarised in 
Table 1. Overall, the quality (including size and need for endarterectomy) of targets grafted 
using the RA was not superior to targets grafted using SVG in the SVG group. Supplementary 
Table 1 summarises graft’s configuration and target’s details in subjects receiving the RA to 
supplement SITA and BITA grafts respectively. When the RA was used to supplement SITA 
graft, it was preferentially used to graft the circumflex artery (65%) followed by the right 
coronary artery (22%). When the RA was used to supplement BITA grafts, it was preferentially 
used to graft the right coronary artery (64%) followed by the circumflex artery (25%). 
RA usage variation across surgeons and centres 
The present post-hoc analysis included a total of 157 participating surgeons) and 28 cardiac 
centres. The use of the RA over SVG only significantly varied across surgeons (Supplementary 
Figure 1, information not available in 120 cases marked as #1) and across different centres 
Supplementary Figure 2).  
PS matching 
Before matching the RA and SVG groups showed significant differences in terms of 
preoperative nitrates administration, age, functional NYHA class, rate of BITA grafts usage, 
BMI, diabetes and preoperative LVEF. Patients receiving the RA were two years younger and 
more likely to have insulin dependent diabetes and decreased LVEF. After PS matching the 
two groups were comparable for all pre-treatment characteristics (Table 2, Figure 1).  
Hospital outcomes 
  
Hospital outcomes are reported in Table 3. Mortality rates and postoperative complications 
were comparable between the two groups.  
5 year-outcomes 
5-years outcomes are reported in Table 4. The rate of MACE was 8.8%(6.5-11.0) versus 
13.6%(10.8-16.3) in the RA and SVG groups respectively. The use of the RA was associated 
with significant risk reduction of MACE (HR 0.60; 95%CI 0.41-0.85; P= 0.005). This result 
was mainly determined by a significant risk reduction in repeat revascularization in the RA 
group (4.4%; 95%CI 2.8-6.0) when compared to the SVG group (7.6%; 95%CI 5.5- 9.7) (HR 
0.59; 95%CI 0.36-0.95; P=0.03) (Figure 2). When compared to the SVG group, the RA group 
had a non-significant lower risk of MI (HR 0.68; 95%CI 0.34-1.38; P=0.30), CV death (HR 
0.83; 95%CI 0.46-1.51; P=0.55) and overall death (HR 0.83; 95%CI 0.54-1.27; P= 0.39). The 
RA remained associated with a lower incidence of MACE also when the analysis accounted 
for the clustering by individual surgeons (mixed effect HR 0.55; 95%CI 0.35-0.87; P=0.01) 
and hospital (mixed effect HR 0.59; 95%CI 0.41-0.86; P=0.005). When the analysis was 
restricted to patintes requiring grafts only to the left coronary system, there was a a larger but 
not significant lower risk for the RA group (HR 0.25; 95%CI 0.05-1.17). We saw no additional 
benefit of using the RA without additional SVG (HR 0.71; 95%CI 0.46-1.10) when compared 
to the RA with additional SVG (HR 0.40; 95%CI 0.20-0.78).    
Postoperative medications  
Medications prescribed at discharge are reported in Supplementary Table 2. Patients receiving 
the RA were more likely to be discharged on CCA although only 29% of them received CCA. 
At 5-year follow-up only 112 patients in the RA group were on CAA of which 44 patients were 
initially discharged on CCA. Patients in the SVG group were more likely to be discharged on 
dual-antiplatelet therapy with clopidogrel. After adjustment for medications prescribed at 
discharge, the use of the RA remained associated with lower 5-year MACE rates (adjusted HR 
  
0.59; 95%CI 0.39-0.91; P=0.01).  Among patients receiving the RA, CCA prescribed at 
discharge was associated with a numerically lower incidence of MACE (5.2% vs 10.2%; P=0.2; 
Figure 3).  
Effect modifiers on RA benefit 
None of possible effect modifiers investigated was found to have influence the effect of the 
RA on MACE when compared to SVG only (Figure 4). Subgroup analysis showed that the 
association between the RA and lower risk of MACE was present for both SITA and BITA 
grafts (interaction P=0.62; Supplementary Table 3, Supplementary Figure 3 and 
Supplementary Figure 4).  
Angiographic follow-up 
Angiographic follow-up was performed only in symptomatic patients and therefore patency 
rates of different conduits could not be analysed. For those who underwent repeat 
revascularization, clinical presentation and revascularization strategy adopted were not 
available in all cases. In the RA group, graft failure and native coronary disease progression 
were documented in 4 and 21 cases respectively among 27 cases of repeat revascularization. 
In the SVG group, graft failure and native coronary disease progression were documented in 
54 and 90 cases respectively among 152 cases of repeat revascularization. All failed grafts were 
reported to be SVG. In the RA group, need for re-CABG and re-PCI was documented in 2 and 
23 cases respectively. In the SVG group, need for re-CABG and re-PCI was documented in 6 
and 113 cases respectively. 
 
Discussion 
The main finding of the present analysis is that the RA (with or without additional vein graft) 
used to supplement either SITA and BITA grafts instead of SVG only, was associated with a 
significant reduction of major adverse cardiac events with a significantly lower rate of 
  
reintervention and marginal reduction in CV death and subsequent MI despite the quality of 
RA targets was not superior to SVG targets. On the other hand, the RA did not increase 
operative mortality and complications.  
Although several randomized trials have shown that the RA is associated with superior 5 year 
patency rates when compared to SVGs [3,4], whether this translates into better clinical 
outcomes remains uncertain. In fact current randomized controlled trials are limited by small 
sample sizes and the results are inconclusive. The Radial Artery Versus Saphenous Vein 
Patency Randomized (RSVP) Trial [4] compared 82 and 60 patients randomized to receive the 
SITA and RA grafts or SITA and SVGs. The only robust clinical outcome assessed was 
mortality. The 5-year survival rate was 94.4%, with no significant difference in survival 
between the 2 groups. In the Radial Artery Patency and Clinical Outcome (RAPCO) Study [5] 
, patients aged 70 years or more were randomly assigned to receive either SITA and RA grafts 
(n=73) or SITA and SVGs grafts (n=80). At 5-year follow-up, cardiac event-free survival 
estimates were 0.84 (95% CI 0.64-0.99) for the RA subgroup and 0.89 (95% CI 0.72-0.99) for 
the SVG subgroup. Petrovic et al. [6] randomized 200 to receive either SITA and RA grafts or 
SITA and SVGs. they found no difference in 8 year clinical outcomes. In a larger trial by 
Goldman et al [21] 757 patients were randomly assigned to receive either SITA and RA grafts 
(n=366) or SITA and SVGs grafts (n=367). There was no significant difference between the 2 
groups at 1 year in terms of death, myocardial infarction, stroke, and repeat coronary 
revascularization. However, outcomes beyond 1 year are not available.  
On the other hand, several retrospective studies that investigated the effect of the RA used as 
additional arterial conduit instead of SVG reported discordant results for survival. Schwann at 
al. [7] compared SITA+RA and SITA+SVG in two institutional US cohorts. Kaplan-Meier 
survival was significantly better for radial artery grafting (P < 0.001). Hayward et al. [8] 
compared 1832 patients who received at least one RA graft in addition to SITA with 749 (29%) 
  
who received SITA and veins only from a multicentre database. At 7 years, survival rates 
between the radial and vein groups were similar (radial: 75 ± 2.6% vs vein: 74 ± 2.9%, P = 
0.65). A few studies have investigated the effect on survival of using the RA in the context of 
BITA grafting with conflicting results. Di Mauro and colleagues [12] reported survivals at 
8 years of 91.9% ± 2.9% among 87 patients undergoing BITA+RA grafting and 95.6% ± 0.9% 
among patients undergoing BITA+SVG (P = 0.12). More recently, Grau and coworkers [13] 
published a series of 183 patients undergoing BITA+RA grafting. Long-term survivals in the 
BITA+RA groups were comparable to those in the BITA+SVG groups (P = .25). Mohammadi 
and associates [14] recently reported comparable long-term survivals in 249 matched pairs of 
patients undergoing BITA+RA versus BITA+SVG (P = 0.44). Shi at al. [15] compared 262 
matched patient-pairs of BITA+RA and BITA+SVG. BITA+RA and at 15 years, BITA + RA 
patients experienced improved risk-adjusted survival (72 ± 6.0% vs 82 ± 5.2%, P = 0.02). 
Finally we recently reported a longer term survival comparison in 275 matched patient-pairs 
of BITA+RA and BITA+SVG from a single institution [16] and the two groups showed 
comparable 15 year survival rates (log-rank P = 0.54).  
The present post-hoc ART analysis support the hypothesis that an additional RA reduces 
reduced mid-term major adverse cardiac events when used to supplement either SITA or BITA 
grafts when compared to SVG only. However, the benefit from the RA was more relevant in 
patients receiving SITA graft who presented a non-significant reduction in CV and overall 
mortality when compared to those receiving SVG. The observed improved clinical outcomes 
in patients receiving the RA can be attributed to its superior patency rate when compared to 
SVG [2,3,22]. Moreover, it has been shown that the RA grafting has a strong protective effect 
against progression of native coronary artery disease in previously grafted vessels which can 
translate into reduced incidence of adverse cardiac events [23].  
  
An interim analysis of the ART trial [1] has shown that BITA grafts did not improve 5 year 
outcomes when compared to a SITA strategy. However, the primary endpoint of the ART is 
10-year survival and those data will be needed to draw any conclusions on whether there is any 
potential benefit of BITA grafts over the long term. Previous studies have supported the 
hypothesis that the beneficial effect from BITA on clinical outcomes may be delayed by as 
much as 7 to 10 years [24].  On the other hand, the RA graft is simple to perform as its calibre 
and handling properties are similar to vein grafts. The superior patency rate of the RA over 
SVGs at 5 years has been largely demonstrated by several randomized controlled trials [2] and 
the use of the RA has been reported to exhibit maximal benefit between 0.5 and 5 years [7]. 
Main limitations of the present analysis are the nonrandomized comparison and the low number 
of outcome events. Propensity score model included several variables but we cannot exclude a 
residual selection bias based on a nonmeasurable ‘‘eye-balling’.  
In conclusion, the present post-hoc analysis of the ART showed that the use of an additional 
RA to supplement both SITA and BITA grafts was associated with a reduction of MACE at 5 
years. Based on these results, it seems reasonable to consider the RA a valid option for multiple 
arterial grafting. 
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Figure Legend 
Figure 1. Changes in standardized mean difference (SMD) between the radial artery (RA) and 
the saphenous vein graft (SVG) groups before and after propensity score matching (SMD: 
standardized mean difference; BMI: Body mass index; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; NYHA: New York Heart Association; UA: unstable angina; COPD: 
Chronic obstructive pulmonary disease; PVD: peripheral vascular disease; TIA: transint 
ischemic attack; CVA: cerebrovascular accident; MI: myocardial infarction; PCI: percutaneous 
coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; DAPT: 
dual antiplatelet therapy; BITA bilateral internal thoracic artery; LMSD: left main stem 
disease; LAD: left anterior descending artery disease; CX: circumflex disease; DIA: diagonal 
branch disease; RCA: right coronary artery disease).  
Figure 2. Cumulative incidence of myocardial infarction (MI), revascularization, 
cardiovascular (CV) death and the composite of major adverse cardiac event (MACE) in the 
Radial artery (RA) and Saphenous Vein Graft (SVG) group respectively after matching.  
Figure 3. Cumulative incidence of the composite of major adverse cardiac event (MACE) in 
the Radial artery (RA) according to calcium channel antagonists (CCA) prescribed at 
discharge.  
Figure 4. Subgroup analysis and interaction analysis on the effect of the radial artery (RA) over 
saphenous vein graft (SVG) on the composite of major adverse cardiac event (MACE) 
  
  
Table 1. Conduits and relative targets details in the RA (top) and SVG (bottom) groups  
* for LITA and RITA, numbers refer to non in-situ configuration 
LITA: left internal thoracic artery; RA: radial artery; RITA: right internal thoracic artery; SVG: 
saphenous vein graft; CX: circumflex; LAD: left anterior descending artery; DIA; diagonal 
branch; RCA: right coronary artery   
 RA group (n=632) 
 LITA other RA RITA SVG 
N conduits used 627 4 362 278 235 
N of distal anastomosis  700 4 789 291 316 
Sequential anastomosis  131 (18.7) 2 ( 50.0) 163 (20.7) 27 ( 9.3) 21 ( 6.6) 
Proximal Anastomosis* n(%)       
 Aorta  34 (16.3) 1 ( 25.0) 574 (73.4) 20 (16.8) 304 (97.1) 
 Other conduit 175 (83.7) 3 ( 75.0) 208 (26.6) 99 (83.2) 9 ( 2.9) 
 Target n (%)      
        CX  130 (18.6) 2 ( 50.0) 394 (49.9) 123 (42.3) 75 (23.7) 
        DIA  75 (10.7) 0 (  0.0) 75 ( 9.5) 21 ( 7.2) 57 (18.0) 
        LAD 493 (70.4) 0 (  0.0) 24 ( 3.0) 133 (45.7) 2 ( 0.6) 
        RCA 2 ( 0.3) 2 ( 50.0) 296 (37.5) 14 ( 4.8) 182 (57.6) 
Vessel_diameter (mean (sd)) 1.79 (0.35) 1.75 (0.20) 1.73 (0.38) 1.79 (0.37) 1.70 (0.33) 
Vessel quality n (%)      
        Good  287 (41.5) 2 ( 50.0) 296 (37.9) 102 (35.5) 141 (45.8) 
        Satisfactory 327 (47.3) 1 ( 25.0) 419 (53.6) 144 (50.2) 135 (43.8) 
        Poor 78 (11.3) 1 ( 25.0) 66 ( 8.5) 41 (14.3) 32 (10.4) 
Endarterectomy n (%) 1 ( 0.1) 0 (  0.0) 10 ( 1.3) 4 ( 1.4) 2 ( 0.6) 
      
      
 SVG group (n=2105) 
 LITA other RA RITA SVG 
N conduits used 2079 0 0 801 2015 
N of distal anastomosis  2221 0 0 825 3877 
Sequential anastomosis 182 ( 8.2) - - 43 ( 5.2) 271 ( 7.0) 
Proximal Anastomosis* n(%)  - -   
Aorta  48 (16.7) - - 66 (22.2) 3713 (96.2) 
Other conduit 237 (82.3) - - 229 (77.1) 145 ( 3.8) 
Target n (%)      
        CX  356 (16.0)   377 (45.7) 1673 (43.2) 
        DIA  176 ( 7.9) - - 53 ( 6.4) 480 (12.4) 
        LAD 1687 (76.0) - - 378 (45.8) 71 ( 1.8) 
        RCA 2 ( 0.1) - - 17 ( 2.1) 1653 (42.6) 
Vessel_diameter (mean (sd)) 1.86 (0.46) - - 1.87 (0.44) 1.83 (0.51) 
Vessel quality      
       Good 1048 (48.1) - - 397 (49.2) 1816 (47.7) 
       Satisfactory 813 (37.3) - - 295 (36.6) 1555 (40.9) 
       Poor 317 (14.6) - - 115 (14.3) 433 (11.4) 
Endarterectomy (%) 10 ( 0.5) - - 3 ( 0.4) 32 ( 0.8) 
  
Table 2. Baseline characteristics in the RA and unmatched and matched SVG group respectively with relative P value and standardized mean 
difference.   
 RA group SVG group 
(unmatched) 
P SMD SVG group 
(matched) 
P SMD 
N 632 2105   632   
Age (mean (sd)) 62.30 (9.08) 64.01 (8.88) <0.001 0.190 62.64 (8.96) 0.51 0.037 
Female, n(%) 80 (12.7) 288 (13.7) 0.55 0.030 80 (12.7) 1.000 <0.001 
BMI (mean (sd)) 28.63 (4.01) 28.13 (3.97) 0.006 0.124 28.85 (4.24) 0.32 0.056 
SBP (mean (sd)) 132.49 (18.85) 131.56 (17.82) 0.26 0.050 132.14 (18.22) 0.74 0.019 
DBP (mean (sd)) 74.98 (11.37) 74.98 (10.91) 0.99 0.001 74.30 (10.95) 0.28 0.061 
Creatinine mmol/L (mean (sd)) 96.00 (20.97) 97.23 (21.87) 0.21 0.057 96.43 (21.20) 0.72 0.020 
NYHA III/IV , n(%) 106 (16.8) 478 (22.7) 0.002 0.150 102 (16.1) 0.82 0.017 
UA , n(%) 41 ( 6.5) 166 ( 7.9) 0.28 0.054 48 ( 7.6) 0.51 0.043 
Treated Hypertension , n(%) 471 (74.5) 1653 (78.5) 0.04 0.095 471 (74.5) 1.00 <0.001 
Treated Hyperlipaemia , n(%) 588 (93.0) 1981 (94.1) 0.37 0.044 590 (93.4) 0.91 0.013 
Diabetes,  n(%)   0.07 0.099  0.97 0.014 
   No history of diabetes 465 (73.6) 1614 (76.7)   461 (72.9)   
   Insulin dependent diabetes  46 ( 7.3) 106 ( 5.0)   47 ( 7.4)   
   Non insulin dependent diabetes  121 (19.1) 385 (18.3)   124 (19.6)   
Smoking, n(%)   0.47 0.056  0.91 0.025 
    Current smoking   94 (14.9) 290 (13.8)   89 (14.1)   
    Ex-smoker  345 (54.6) 1207 (57.3)   351 (55.5)   
    Never smoked  193 (30.5) 608 (28.9)   192 (30.4)   
COPD , n(%) 11 ( 1.7) 60 ( 2.9) 0.16 0.074 12 ( 1.9) 1.00 0.012 
Asthma, n(%) 30 ( 4.7) 88 ( 4.2) 0.61 0.027 28 ( 4.4) 0.89 0.015 
PVD, n(%) 45 ( 7.1) 148 ( 7.0) 1.00 0.003 51 ( 8.1) 0.60 0.036 
TIA, n(%) 19 ( 3.0) 85 ( 4.0) 0.28 0.056 13 ( 2.1) 0.37 0.060 
CVA, n(%) 15 ( 2.4) 67 ( 3.2) 0.36 0.049 12 ( 1.9) 0.70 0.033 
MI, n(%) 260 (41.1) 891 (42.3) 0.63 0.024 269 (42.6) 0.65 0.029 
PCI, n(%) 86 (13.6) 332 (15.8) 0.21 0.061 91 (14.4) 0.75 0.023 
  
AF pre, n(%) 8 ( 1.3) 32 ( 1.5) 0.78 0.022 11 ( 1.7) 0.64 0.039 
LVEF pre, n(%)   0.09 0.100  0.88 0.028 
     ≥50% 454 (71.8) 1602 (76.1)   446 (70.6)   
    31-49% 163 (25.8) 456 (21.7)   170 (26.9)   
    ≤30%  15 ( 2.4) 47 ( 2.2)   16 ( 2.5)   
DAPT pre, n(%) 135 (21.4) 484 (23.0) 0.42 0.039 152 (24.1) 0.28 0.064 
Antiplatelet within 3 days , n(%) 96 (15.2) 350 (16.6) 0.43 0.039 91 (14.4) 0.75 0.022 
Nitrates pre , n(%) 249 (39.4) 1079 (51.3) <0.001 0.240 255 (40.3) 0.77 0.019 
OFF-PUMP , n(%)   239 (37.8) 842 (40.0) 0.35 0.045 247 (39.1) 0.69 0.026 
BITA , n(%) 273 (43.2) 775 (36.8) 0.004 0.130 272 (43.0) 1.00 0.003 
LMSD, n(%) 142 (22.5) 410 (19.5) 0.11 0.074 134 (21.2) 0.63 0.031 
LAD, n(%) 625 (98.9) 2073 (98.5) 0.56 0.036 625 (98.9) 1.00 <0.001 
CX , n(%) 581 (91.9) 1952 (92.7) 0.56 0.030 576 (91.1) 0.69 0.028 
DIA, n(%) 221 (35.0) 691 (32.8) 0.34 0.045 228 (36.1) 0.72 0.023 
RCA , n(%) 469 (74.2) 1598 (75.9) 0.41 0.039 473 (74.8) 0.85 0.015 
N grafts (%)   0.84 0.053  0.82 0.070 
  2  69 (10.9) 246 (11.7)   78 (12.3)   
  3  332 (52.5) 1119 (53.2)   314 (49.7)   
  4  191 (30.2) 630 (29.9)   201 (31.8)   
  5  38 ( 6.0) 104 ( 4.9)   36 ( 5.7)   
  6  2 ( 0.3) 6 ( 0.3)   3 ( 0.5)   
RA: radial artery; SVG: saphenous vein graft; SMD: standardized mean difference; BMI: Body mass index; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; NYHA: New York Heart Association; UA: unstable angina; COPD: Chronic obstructive pulmonary disease; PVD: 
peripheral vascular disease; TIA: transint ischemic attack; CVA: cerebrovascular accident; MI: myocardial infarction; PCI: percutaneous 
coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; DAPT: dual antiplatelet therapy; BITA bilateral internal 
thoracic artery; LMSD: left main stem disease; LAD: left anterior descending artery; CX: circumflex; DIA: diagonal; RCA: right coronary 
artery.  
  
  
Table 3. Hospital outcomes  
 RA group SVG group 
(unmatched) 
P* SVG group 
(matched) 
Pǂ 
N 632 2105  632  
Death, n(%)  9 (1.4) 20 (1.0) 0.42 5 (0.8) 0.42 
Return to theatre, n(%)  27 (4.3) 72 (3.4) 0.38 19 (3.0) 0.29 
IABP post, n(%)  21 (3.3) 91 (4.3) 0.32 29 (4.6) 0.31 
Renal replacement therapy, n(%)  45 (7.1) 100 (4.8) 0.03 36 (5.7) 0.36 
Sternal wound infection, n(%)  25 (4.0) 67 (3.2) 0.41 19 (3.0) 0.44 
MI, n(%)  6 (0.9) 40 (1.9) 0.15 15 (2.4) 0.08 
CVA, n(%)  5 (0.8) 31 (1.5) 0.26 5 (0.8) 1.00 
Repeat Revascularization, n(%)  2 (0.3) 13 (0.6) 0.55 5 (0.8) 0.45 
POAF, n(%)  152 (24.1) 524 (24.9) 0.71 165 (26.1) 0.44 
*chi squared test (binary outcomes) and paired t-test (continuous outcomes) 
ǂ McNemar's test (binary outcomes) and paired t-test (continuous outcomes) 
RA: Radial artery; SVG: saphenous vein graft; IABP: intra-aortic balloon pump; MI: myocardial infarction; CVA: cerebral vascular accident; 
POAF: postoperative atrial fibrillation.  
  
  
Table 4. Five-year outcomes rates (95% confidence interval, CI) 
 RA group SVG group 
(unmatched) 
P* SVG group 
(matched) 
Pǂ 
n 632 2105  632  
MI 14 (2.3%[1.1-3.4]) 78(3.7%[2.9-4.6]) 0.07 21(3.4%[2.0-4.8]) 0.30 
Repeat revascularization 27(4.4%[2.8-6.0]) 152(7.3%[6.2-8.5]) 0.008 47(7.6%[5.5- 9.7) 0.033 
CV death 22(3.5%[2.1-5.0]) 73(3.5%[2.7-4.3]) 0.99 25(4.0%[2.5-5.6]) 0.55 
Overall death 45 (7.3%(5.2-9.3]) 189(9.2%[7.9-10.4]) 0.15 51(8.3%[6.1-10.5]) 0.39 
CV death/MI/repeat revascularization 53(8.8%[6.5--11.0]) 261 (12.9%[11.4-14.3]) 0.005 82(13.6%[10.8-16.3]) 0.005 
* unadjusted Cox model 
ǂ Cox model stratified for matched pairs   
RA: radial artery; SVG: saphenous vein graft; CV: cardiovascular; MI: myocardial infarction 
 
 
